Literature DB >> 9391124

Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins.

S Takemoto1, J C Mulloy, A Cereseto, T S Migone, B K Patel, M Matsuoka, K Yamaguchi, K Takatsuki, S Kamihira, J D White, W J Leonard, T Waldmann, G Franchini.   

Abstract

Human T cell leukemia/lymphotropic virus type I (HTLV-I) induces adult T cell leukemia/lymphoma (ATLL). The mechanism of HTLV-I oncogenesis in T cells remains partly elusive. In vitro, HTLV-I induces ligand-independent transformation of human CD4+ T cells, an event that correlates with acquisition of constitutive phosphorylation of Janus kinases (JAK) and signal transducers and activators of transcription (STAT) proteins. However, it is unclear whether the in vitro model of HTLV-I transformation has relevance to viral leukemogenesis in vivo. Here we tested the status of JAK/STAT phosphorylation and DNA-binding activity of STAT proteins in cell extracts of uncultured leukemic cells from 12 patients with ATLL by either DNA-binding assays, using DNA oligonucleotides specific for STAT-1 and STAT-3, STAT-5 and STAT-6 or, more directly, by immunoprecipitation and immunoblotting with anti-phosphotyrosine antibody for JAK and STAT proteins. Leukemic cells from 8 of 12 patients studied displayed constitutive DNA-binding activity of one or more STAT proteins, and the constitutive activation of the JAK/STAT pathway was found to persist over time in the 2 patients followed longitudinally. Furthermore, an association between JAK3 and STAT-1, STAT-3, and STAT-5 activation and cell-cycle progression was demonstrated by both propidium iodide staining and bromodeoxyuridine incorporation in cells of four patients tested. These results imply that JAK/STAT activation is associated with replication of leukemic cells and that therapeutic approaches aimed at JAK/STAT inhibition may be considered to halt neoplastic growth.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9391124      PMCID: PMC28404          DOI: 10.1073/pnas.94.25.13897

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  42 in total

1.  STAT3beta, a splice variant of transcription factor STAT3, is a dominant negative regulator of transcription.

Authors:  E Caldenhoven; T B van Dijk; R Solari; J Armstrong; J A Raaijmakers; J W Lammers; L Koenderman; R P de Groot
Journal:  J Biol Chem       Date:  1996-05-31       Impact factor: 5.157

Review 2.  Reflections on STAT3, STAT5, and STAT6 as fat STATs.

Authors:  J E Darnell
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

3.  STATs and cytokine specificity.

Authors:  W J Leonard
Journal:  Nat Med       Date:  1996-09       Impact factor: 53.440

4.  Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor.

Authors:  N Meydan; T Grunberger; H Dadi; M Shahar; E Arpaia; Z Lapidot; J S Leeder; M Freedman; A Cohen; A Gazit; A Levitzki; C M Roifman
Journal:  Nature       Date:  1996-02-15       Impact factor: 49.962

5.  Stat6 and Jak1 are common elements in platelet-derived growth factor and interleukin-4 signal transduction pathways in NIH 3T3 fibroblasts.

Authors:  B K Patel; L M Wang; C C Lee; W G Taylor; J H Pierce; W J LaRochelle
Journal:  J Biol Chem       Date:  1996-09-06       Impact factor: 5.157

6.  Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines.

Authors:  R M Weber-Nordt; C Egen; J Wehinger; W Ludwig; V Gouilleux-Gruart; R Mertelsmann; J Finke
Journal:  Blood       Date:  1996-08-01       Impact factor: 22.113

7.  Clonal expansion of human T-cell leukemia virus type I-infected cells in asymptomatic and symptomatic carriers without malignancy.

Authors:  E Wattel; J P Vartanian; C Pannetier; S Wain-Hobson
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

Review 8.  Immunodeficiencies caused by genetic defects in protein kinases.

Authors:  L D Notarangelo
Journal:  Curr Opin Immunol       Date:  1996-08       Impact factor: 7.486

9.  STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients.

Authors:  V Gouilleux-Gruart; F Gouilleux; C Desaint; J F Claisse; J C Capiod; J Delobel; R Weber-Nordt; I Dusanter-Fourt; F Dreyfus; B Groner; L Prin
Journal:  Blood       Date:  1996-03-01       Impact factor: 22.113

10.  Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma.

Authors:  B J Poiesz; F W Ruscetti; A F Gazdar; P A Bunn; J D Minna; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1980-12       Impact factor: 11.205

View more
  77 in total

1.  Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter.

Authors:  Q Zhang; P N Raghunath; E Vonderheid; N Odum; M A Wasik
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

Review 2.  Mature T-cell leukemias: Molecular and Clinical Aspects.

Authors:  Nathanael G Bailey; Kojo S J Elenitoba-Johnson
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

Review 3.  Comparative biology of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2.

Authors:  Gerold Feuer; Patrick L Green
Journal:  Oncogene       Date:  2005-09-05       Impact factor: 9.867

4.  Transforming growth factor-beta downregulates interleukin-2-induced phosphorylation of signal transducer and activator of transcription 5 in human renal cell carcinoma.

Authors:  Cheryn Song; Sun-Young Jun; Jun-Hyuk Hong; Hanjong Ahn
Journal:  J Cancer Res Clin Oncol       Date:  2007-02-06       Impact factor: 4.553

Review 5.  Human T-lymphotropic virus proteins and post-translational modification pathways.

Authors:  Carlo Bidoia
Journal:  World J Virol       Date:  2012-08-12

6.  Human and simian T-cell leukemia viruses type 2 (HTLV-2 and STLV-2(pan-p)) transform T cells independently of Jak/STAT activation.

Authors:  J C Mulloy; T S Migone; T M Ross; N Ton; P L Green; W J Leonard; G Franchini
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

7.  Human T-cell leukemia virus type 1 pX-I and pX-II open reading frames are dispensable for the immortalization of primary lymphocytes.

Authors:  M D Robek; F H Wong; L Ratner
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

Review 8.  T-cell control by human T-cell leukemia/lymphoma virus type 1.

Authors:  Genoveffa Franchini; Risaku Fukumoto; Jake R Fullen
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

9.  Malignant transformation of CD4+ T lymphocytes mediated by oncogenic kinase NPM/ALK recapitulates IL-2-induced cell signaling and gene expression reprogramming.

Authors:  Michal Marzec; Krzysztof Halasa; Xiaobin Liu; Hong Y Wang; Mangeng Cheng; Donald Baldwin; John W Tobias; Stephen J Schuster; Anders Woetmann; Qian Zhang; Suzanne D Turner; Niels Ødum; Mariusz A Wasik
Journal:  J Immunol       Date:  2013-11-11       Impact factor: 5.422

Review 10.  Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms.

Authors:  Ehab Atallah; Srdan Verstovsek
Journal:  Expert Rev Anticancer Ther       Date:  2009-05       Impact factor: 4.512

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.